Skip to main content

Table 3 Activity, efficacy and effectiveness of FIr-B/FOx regimen according to KRAS genotype

From: Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

  c.35 G>A
KRASmutant
other
KRASmutant
KRASwild-type
  Intent-to-treat
analysis
Intent-to-treat
analysis
Intent-to-treat
analysis
  Number % Number % Number %
Enrolled pts 15 100 13 100 31 100
Evaluable pts 14 93 13 100 30 97
Objective response 10 71 (CI ± 26) 8 61 (CI ± 26) 27 90 (CI ± 11)
   partial response 9 64 8 61 23 76
   complete response 1 7 - - 4 13
Stable disease 3 21 2 15 2 7
Progressive disease 1 7 3 23 1 3
Median PFS, months 9   12   14  
   range 1+-60+   3-37   1+-69+  
   progression events 10 67 12 92 25 81
Median OS, months 14   39   38  
   range 1+-60+   8-59+   1+-69+  
   deaths 10 67 8 61.5 17 55
Liver metastasectomies 2   5   11  
   number/overall pts 2/15 13 5/13 38 11/31 35
   number/Pts with liver metastases 2/12 17 5/8 62.5 11/19 58
   number/Pts with L-L metastases 2/6 33 5/7 71 10/12 83
Pathologic complete responses - - 2 40 - -
  1. L-L, liver-limited; OS, overall survival; PFS, progression-free survival; pts, patients.